1. Angulo P.. 2002;Nonalcoholic fatty liver disease. N Engl J Med 346:1221-1231. PMID:
11961152.
2. Kim S. H., Lee J. W., Hwang H. J.. 2011;Associations between combinations of body mass index plus nonalcoholic fatty liver disease and diabetes mellitus among Korean adults. Asia Pac J Clin Nutr 20:14-20. PMID:
21393105.
3. Tessari P., Coracina A., Cosma A., Tiengo A.. 2009;Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 19:291-302. PMID:
19359149.
4. Greco D., Kotronen A., Westerbacka J., Puig O., Arkkila P., Kiviluoto T., Laitinen S., Kolak M., Fisher R. M., Hamsten A., Auvinen P., Yki-Järvinen H.. 2008;Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol 294:G1281-1287. PMID:
18388185.
5. Fabbrini E., Magkos F., Mohammed B. S., Pietka T., Abumrad N. A., Patterson B. W., Okunade A., Klein S.. 2009;Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A 106:15430-15435. PMID:
19706383.
6. Ueno T., Sugawara H., Sujaku K., Hashimoto O., Tsuji R., Tamaki S., Torimura T., Inuzuka S., Sata M., Tanikawa K.. 1997;Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 27:103-107. PMID:
9252081.
7. Hickman I. J., Jonsson J. R., Prins J. B., Ash S., Purdie D. M., Clouston A. D., Powell E. E.. 2004;Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 53:413-419. PMID:
14960526.
8. Gerber L., Otgonsuren M., Mishra A., Escheik C., Birerdinc A., Stepanova M., Younossi Z. M.. 2012;Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study. Aliment Pharmacol Ther 36:772-781. PMID:
22958053.
9. Zelber-Sagi S., Nitzan-Kaluski D., Goldsmith R., Webb M., Zvibel I., Goldiner I., Blendis L., Halpern Z., Oren R.. 2008;Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatology 48:1791-1798. PMID:
18972405.
10. Schultz A., Mendonca L. S., Aguila M. B., Mandarim-de-Lacerda C. A.. 2012;Swimming training beneficial effects in a mice model of nonalcoholic fatty liver disease. Exp Toxicol Pathol 64:273-282. PMID:
20869214.
11. Johnson N. A., Sachinwalla T., Walton D. W., Smith K., Armstrong A., Thompson M. W., George J.. 2009;Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 50:1105-1112. PMID:
19637289.
12. Folch J., Lees M., Sloane , Stanley G. H.. 1957;A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226:497-509. PMID:
13428781.
13. American Gastroenterological Association. 2002;American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. Gastroenterology 123:1702-1704. PMID:
12404244.
14. Church T. S., Kuk J. L., Ross R., Priest E. L., Biltoff E., Blair S. N.. 2006;Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. Gastroenterology 130:2023-2030. PMID:
16762625.
15. Do G. M., Oh H. Y., Kwon E. Y., Cho Y. Y., Shin S. K., Park H. J., Jeon S. M., Kim E., Hur C. G., Park T. S., Sung M. K., McGregor R. A., Choi M. S.. 2011;Long-term adaptation of global transcription and metabolism in the liver of high-fat diet-fed C57BL/6J mice. Mol Nutr Food Res 55(Suppl. 2):S173-185. PMID:
21618427.
16. Brown M. S., Goldstein J. L.. 2008;Selective versus total insulin resistance: a pathogenic paradox. Cell Metab 7:95-96. PMID:
18249166.
17. Chen G., Liang G., Ou J., Goldstein J. L., Brown M. S.. 2004;Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proc Natl Acad Sci U S A 101:11245-11250. PMID:
15266058.
18. Utzschneider K. M., K. M. S. E.. 2006;Review: The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 91:4753-4761. PMID:
16968800.
19. Gulick T., Cresci S., Caira T., Moore D. D., Kelly D. P.. 1994;The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci U S A 91:11012-11016. PMID:
7971999.
20. Hashimoto T., Cook W. S., Qi C., Yeldandi A. V., Reddy J. K., Rao M. S.. 2000;Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. J Biol Chem 275:28918-28928. PMID:
10844002.
21. Purushotham A., Schug T. T., Xu Q., Surapureddi S., Guo X., Li X.. 2009;Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab 9:327-338. PMID:
19356714.
22. Viollet B., Foretz M., Guigas B., Horman S., Dentin R., Bertrand L., Hue L., Andreelli F.. 2006;Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J Physiol 574(Pt 1):41-53. PMID:
16644802.
23. Takekoshi K., Fukuhara M., Quin Z., Nissato S., Isobe K., Kawakami Y., Ohmori H.. 2006;Long-term exercise stimulates adenosine monophosphate-activated protein kinase activity and subunit expression in rat visceral adipose tissue and liver. Metabolism 55:1122-1128. PMID:
16839850.
24. Hou X., Xu S., Maitland-Toolan K. A., Sato K., Jiang B., Ido Y., Lan F., Walsh K., Wierzbicki M., Verbeuren T. J., Cohen R. A., Zang M.. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein
kinase. 2008;J Biol Chem 283:20015-20026. PMID:
18482975.